SCHEMBL2179211

SCHEMBL2179211

Cc1oc(-c2ccccc2)nc1C(=O)Nc1ccc(-c2ccc3c(c2)C(=O)N(C(C(=O)O)C(C)C)C3)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.52
GAA P10253 2/20 0.52
ALDH1A1 P00352 3/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
LMNA P02545 3/20 0.43
TP53 P04637 1/20 0.43
DGAT1 O75907 3/20 0.41
MAPK1 P28482 2/20 0.41
POLB P06746 1/20 0.41
TSHR P16473 1/20 0.41
RAB9A P51151 1/20 0.41
MAPT P10636 2/20 0.41
SDCBP O00560 3/20 0.40
SDC2 P34741 3/20 0.40
SMO Q99835 1/20 0.40
THRB P10828 1/20 0.40
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
TARBP2 Q15633 1/20 0.39
VHL P40337 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2179203 1.00 KDM4E (0.52) KDM4EGAAALDH1A1SMN1; SMN2LMNA
SCHEMBL2180457 0.91 KDM4E (0.46) KDM4EGAAALDH1A1SMN1; SMN2LMNA
SCHEMBL2180133 0.91 KDM4E (0.46) KDM4EGAAALDH1A1SMN1; SMN2LMNA
SCHEMBL2179375 0.89 DGAT1 (0.57) DGAT1
SCHEMBL2178823 0.89 DGAT1 (0.57) DGAT1
SCHEMBL2177089 0.85 LMNA (0.44) GAAALDH1A1SMN1; SMN2LMNATP53
SCHEMBL13719015 0.83 LMNA (0.48) LMNATP53SDCBPSDC2
SCHEMBL2178118 0.83 LMNA (0.48) LMNATP53SDCBPSDC2
SCHEMBL2180113 0.83 LMNA (0.48) LMNATP53SDCBPSDC2
SCHEMBL2179317 0.82 LMNA (0.49) KDM4ELMNATP53MAPTSDCBP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8748426-B2 Inhibitors of diacylglycerol acyl transferase Piramal Enterprises Limited (IN) 2014-06-10 US claimed
US-20120289505-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Enterprises Limited (IN) 2012-11-15 US claimed
EP-2519500-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Healthcare Ltd. (IN) 2012-11-07 EP claimed
WO-2011080718-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE PIRAMAL LIFE SCIENCES LIMITED (IN) 2011-07-07 WO claimed
US-8748426-B2 Inhibitors of diacylglycerol acyl transferase Piramal Enterprises Limited (IN) 2014-06-10 US disclosed
US-20120289505-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Enterprises Limited (IN) 2012-11-15 US disclosed
EP-2519500-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Healthcare Ltd. (IN) 2012-11-07 EP disclosed
WO-2011080718-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE PIRAMAL LIFE SCIENCES LIMITED (IN) 2011-07-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120289505-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE DGAT1, DGAT2, LCAT KDM4E 3647/4885GAA 178/4885ALDH1A1 715/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.